APAlipio Pinto

Alipio Pinto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alipio Pinto has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Jorge Goldstein

    Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Neurofisiopatología, Facultad de Medicina, Universidad de Buenos Aires, Instituto de Fisiología y Biofísica “Houssay” (IFIBIO)

    3 shared publications
  • Alejandro Pizzoni

    Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261

    2 shared publications
  • Adriana Cangelosi

    Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos Malbrán” - ANLIS - Centro Nacional de Control de Calidad de Biológicos, Buenos Aires, Argentina

    1 shared publication
  • Ana B. Celi

    Departamento de Ciencias Fisiológicas, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina

    1 shared publication
  • Ana Belen Ramos Aloi

    CONICET- Universidad de Buenos Aires, Instituto de Fisiología y Biofísica "Houssay" (IFIBIO), Laboratorio de Neurofisiopatología, Buenos Aires, Argentina

    1 shared publication
  • Ana Belén Ramos-Aloi

    Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Neurofisiopatología, Facultad de Medicina, Universidad de Buenos Aires, Instituto de Fisiología y Biofísica “Houssay” (IFIBIO)

    1 shared publication

Latest Publications

  • Open Access

    Becoming Messengers: cAMP, Ca2+, and the Emergence of Cellular Control

    by Alejandro Pizzoni, Alipio Pinto, Daniel L. Altschuler

  • Open Access

    Rap1b Activates Endosomal AC9 to Drive the Second cAMP Wave

    by Xuefeng Zhang, Alejandro Pizzoni, Alipio Pinto, Daniel L. Altschuler

    GsPCR signaling orchestrates cAMP production in three distinct spatial waves originating from the plasma membrane (PM), endosomes, and the nucleus. While the molecular drivers of the PM and nuclear waves are well defined, the regulation of the endosomal cAMP wave remains insufficiently understood. Here, we identify the small GTPase Rap1b as a direct activator of the endosomal adenylyl cyclase 9 (AC9), revealing a novel mechanism for intracellular cAMP synthesis. Like Gαs, Rap1b-GTP interacts with the C2 domain of AC9, allosterically enhancing its catalytic activity both in vitro and in cells. Using AC9 mutations that selectively disrupt Rap1b versus Gαs binding, we elucidate the role of the Rap1b–AC9 unit in mediating the endosomal cAMP wave, introducing a new layer of spatial regulation to cAMP signaling.


  • Deleterious consequences of Shiga toxin in the CNS

    by Ana Belén Ramos-Aloi, Luciana Soledad Arias, Alipio Pinto, Jorge Goldstein

    SUMMARY: The primary objective of this review is to provide an update on the most recent findings concerning the adverse effects of Shiga toxin-producing Escherichia coli (STEC) on the central nervous system (CNS), from both clinical and experimental perspectives. Considered the main predictor of death, STEC encephalopathy plays a critical role in hemolytic uremic syndrome (HUS), which affects between 11% and 64% of HUS patients and considerably increases the risk of morbidity and mortality. Of note, STEC encephalopathy in the absence of HUS has been observed in approximately 5% of cases. The ability of enterohemorrhagic E. coli to adapt to its microenvironment has been responsible for global outbreaks. Once in circulation, Shiga toxin rapidly induces endothelial damage via the Gb3 receptor. Brain inflammation in STEC encephalopathies has been consistently reported and experimentally confirmed. The entry of Shiga toxin into the brain leads to direct neuronal damage through its interaction with neuronal Gb3, as demonstrated in clinical case studies and experimental models. This review also discusses the adverse effects of STEC on the brain, which may arise from metabolic or circulatory disruptions, secondary damage to the CNS, or a multifactorial combination. Recent studies have highlighted the significance of neuroimaging techniques in diagnosing HUS encephalopathy. Efforts have been made to identify early neural biomarkers and develop corresponding treatments. Although various biomarkers have been reported, additional studies are needed for further development and standardization. Late-stage pharmacological treatments for encephalopathy are also discussed, both in clinical settings and experimental research.


  • Shiga toxins from enterohemorrhagic Escherichia coli and anti-GB3 antibody as novel agents against triple negative breast cancer

    by Alipio Pinto, Noelia V. Miret, Ana Belen Ramos Aloi, Florencia Vassallu, Lionel M. Igaz, Andrea S. Randi, Jorge Goldstein


  • Cognitive Deficits Found in a Pro-inflammatory State are Independent of ERK1/2 Signaling in the Murine Brain Hippocampus Treated with Shiga Toxin 2 from Enterohemorrhagic Escherichia coli

    by Clara Berdasco, Alipio Pinto, Mariano G. Blake, Fernando Correa, Nadia A. Longo Carbajosa, Ana B. Celi, Patricia A. Geoghegan, Adriana Cangelosi, Myriam Nuñez, Mariela M. Gironacci, et al.

    Shiga toxin 2 (Stx2) from enterohemorrhagic Escherichia coli (EHEC) produces hemorrhagic colitis, hemolytic uremic syndrome (HUS), and acute encephalopathy. The mortality rate in HUS increases significantly when the central nervous system (CNS) is involved. Besides, EHEC also releases lipopolysaccharide (LPS). Many reports have described cognitive dysfunctions in HUS patients, the hippocampus being one of the brain areas targeted by EHEC infection. In this context, a translational murine model of encephalopathy was employed to establish the deleterious effects of Stx2 and the contribution of LPS in the hippocampus. The purpose of this work is to elucidate the signaling pathways that may activate the inflammatory processes triggered by Stx2, which produces cognitive alterations at the level of the hippocampus. Results demonstrate that Stx2 produced depression-like behavior, pro-inflammatory cytokine release, and NF-kB activation independent of the ERK1/2 signaling pathway, while co-administration of Stx2 and LPS reduced memory index. On the other hand, LPS activated NF-kB dependent on ERK1/2 signaling pathway. Cotreatment of Stx2 with LPS aggravated the pathologic state, while dexamethasone treatment succeeded in preventing behavioral alterations. Our present work suggests that the use of drugs such as corticosteroids or NF-kB signaling inhibitors may serve as neuroprotectors from EHEC infection.